

25 July 2023

Fisher & Paykel

HEALTHCARE

Fisher & Paykel Healthcare Limited
15 Maurice Paykel Place, East Tamaki
P O Box 14 348, Panmure
Auckland, New Zealand
Telephone: +64 9 574 0100
Facsimile: +64 9 574 0158
Website: www.fphcare.com

Manufacturer's Declaration

In relation to Regulation (EU) 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices, in particular with respect to:

- the validity of certificates issued under Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD) or Council Directive 93/42/EEC on Medical Devices (MDD) (Directive Certificates) and/or¹
- the compliance of the devices and us as their manufacturer with the conditions for the continued placing on the market and putting into service

| | |
|--|--|
| Manufacturer name | Fisher & Paykel Healthcare Ltd |
| Manufacturer address and contact details | 15 Maurice Paykel Place East Tamaki, Auckland New Zealand https://www.fphcare.com/nz/corporate/contact-us/ |
| Single Registration Number (SRN) | NZ-MF-000002556 |

| | |
|---|--|
| Authorised Representative name | Fisher & Paykel Healthcare SAS |
| Authorised Representative address and contact details | 10 Avenue du Quebec, Baitment F5, BP 512 Villebon-sur-Yvette, 91946 Coutaboeuf Cedex, France customer.carefrance@fphcare.fr |
| Single Registration Number (SRN) | FR-IM000000488 |

| | |
|---|------------------------------|
| Notified body name | TÜV SÜD Product Service GmbH |
| Notified body number | 0123 |
| Directive Certificate number(s) to which this confirmation is made | G1 010815 0038 |
| Original expiry date as indicated on the Directive Certificate prior to the extension of the validity (if applicable) | 2024-05-26 |
| End date of extended validity/transition period | 2028-12-31 |

¹ The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body.

We, as the manufacturer declare under our sole responsibility:

- for the above listed **Directive Certificate** the conditions for the legal extension of validity as required in Article 120.2 of the MDR are met *and/or*²
- the listed **device(s)** in the attached schedule and we as their manufacturer are in compliance with the conditions listed in Article 120.3c of the MDR for continued placing on the market and putting into service,

namely by fulfilling the following conditions:

➤ **Directive Certificate(s)** as listed above or in the attached schedule

- Directive Certificate(s) covering the listed device(s) was/were issued after 25 May 2017, was/were valid on 26 May 2021 and have not been withdrawn afterwards.

Choose applicable statements:

- Expired *before* 20 March 2023: (not applicable to Fisher & Paykel Healthcare Ltd)
- Before the original date of expiry as indicated on the Directive Certificate(s), we and the notified body have signed written agreement(s) in accordance with Section 4.3, second subparagraph of Annex VII to this Regulation for the conformity assessment(s) in respect of the device(s) covered by the expired certificate(s) or in respect of a device(s) intended to substitute that/those device(s), or
 - A Competent Authority has granted a derogation from the applicable conformity assessment procedure in accordance with Article 59(1) MDR (may be provided upon request), or
 - A Competent Authority has required the manufacturer, in accordance with Article 97(1) MDR, to carry out the applicable conformity assessment procedure (may be provided upon request)

Choose one of the following statements only if a derogation per Article 59(1) or a requirement per Article 97(1) has been granted by a Competent Authority:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

- Expired/expires *after* 20 March 2023:

Choose one applicable statement:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitute(s) and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.

² The first condition is not applicable in case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body

- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

➤ **Unclassified devices** (not applicable to Fisher & Paykel Healthcare Ltd)

In case of devices for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body:

Choose one applicable statement:

- Formal application(s) to the notified body in accordance with Section 4.3, first subparagraph of Annex VII MDR for conformity assessment has/have been made or will be made/submitted by us to a notified body no later than 26 May 2024 for the device(s) listed in the attached schedule or its/their substitutes and signed written agreement(s) is/will be in place in accordance with Section 4.3, second subparagraph of Annex VII MDR before 26 September 2024.
- We do not intent to lodge an application for conformity assessment by 26 May 2024, therefore the transition period will end on 26 May 2024.

➤ **Quality Management System (QMS)**

Choose one applicable statement:

- A QMS in accordance with Article 10(9) MDR will be put in place by no later than 26 May 2024.
- A QMS in accordance with Article 10(9) MDR is in place.
- A notified body has issued the attached certificate for the MDR-compliant QMS.

➤ **Device(s) as listed in the attached schedule**

- The device(s) continue to comply with the AIMDD or MDD.
- There are no significant changes in the design and intended purpose.
- The device(s) do not present an unacceptable risk to health or safety of patients, users or other persons, or to other aspects of the protection of public health.

Signed for and on behalf of the manufacturer:

Fisher & Paykel Healthcare Ltd.
Auckland, New Zealand
www.fphcare.com

Masar Mohammad

Masar Mohammad
Regulatory Affairs Manager
Email: Masar.Mohammad@fphcare.co.nz

Schedule of Devices

The above Manufacturer's Declaration is valid for the following devices:

| Identification of the device(s) ³ (e.g., device name, family/group name, device model or catalogue number)* | Directive Certificate number(s) to which this confirmation is made (if applicable) | Original expiry date as indicated on the Directive Certificate (s) prior to the extension/substitution of the validity (if applicable) | Notified Body name and number that issued the Directive Certificate (if applicable) | Notified Body name and number where the MDR application was lodged/contract signed (if applicable) | End date of extended validity / transition period |
|---|--|--|---|--|---|
| Respiratory Gas Delivery Systems | G1 010815 0038 | 2024-05-26 | TUV SÜD, 0123 | TUV SÜD, 0123 | 2028-12-31 |
| Heated Humidifiers | G1 010815 0038 | 2024-05-26 | TUV SÜD, 0123 | TUV SÜD, 0123 | 2028-12-31 |
| Continuous Positive Airway Pressure Units | G1 010815 0038 | 2024-05-26 | TUV SÜD, 0123 | TUV SÜD, 0123 | 2028-12-31 |
| Gas Powered Pulmonary Resuscitators | G1 010815 0038 | 2024-05-26 | TUV SÜD, 0123 | TUV SÜD, 0123 | 2028-12-31 |
| Nasal and/or Oral Interfaces for Delivery of Respiratory Gases | G1 010815 0038 | 2024-05-26 | TUV SÜD, 0123 | TUV SÜD, 0123 | 2028-12-31 |
| Patient Monitoring Software for Use with Fisher & Paykel Healthcare Medical Devices | G1 010815 0038 | 2024-05-26 | TUV SÜD, 0123 | TUV SÜD, 0123 | 2028-12-31 |
| Insufflation Gas Conditioning Systems | G1 010815 0038 | 2024-05-26 | TUV SÜD, 0123 | TUV SÜD, 0123 | 2028-12-31 |

³ for devices with AIMDD/MDD certificate(s) the identification should be as in the certificate, and only if the certificate has a generic scope it should be as defined above)